Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Share-based Compensation (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Share-based Compensation data on record, last reported at $25264.0 in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 9.09% year-over-year to $25264.0; the TTM value through Dec 2025 reached $22310.0, down 84.76%, while the annual FY2025 figure was $28964.0, 78.97% down from the prior year.
  • Share-based Compensation reached $25264.0 in Q4 2025 per INM's latest filing, up from $20205.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $214779.0 in Q4 2021 and bottomed at -$63613.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $66010.9, with a median of $40467.0 recorded in 2023.
  • Peak YoY movement for Share-based Compensation: grew 26.8% in 2024, then tumbled 263.3% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $214779.0 in 2021, then crashed by 67.11% to $70638.0 in 2022, then plummeted by 74.14% to $18264.0 in 2023, then increased by 26.8% to $23159.0 in 2024, then rose by 9.09% to $25264.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $25264.0 in Q4 2025, $20205.0 in Q3 2025, and -$63613.0 in Q2 2025.